Electromed, Inc. to Participate in LD Micro Main Event XIX
Rhea-AI Summary
Electromed (NYSE American: ELMD) will participate in the LD Micro Main Event XIX conference in San Diego, October 19-21, 2025. CEO Jim Cunniff will present on Monday, October 20, 2025 at 10:00 AM PT.
Investors can watch a live webcast via the Electromed Investor Relations site under Events & Presentations; institutional investors can register for the conference and request one-on-one meetings through LD Micro representatives.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ELMD gained 0.49%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Management will present Monday, October 20, 2025 at 10:00 am PT
New Prague, Minnesota--(Newsfile Corp. - October 13, 2025) - Electromed, Inc. (NYSE American: ELMD) ("Electromed" or the "Company"), a leader in innovative airway clearance technologies, today announced that Company management will participate in the LD Micro Main Event XIX Conference being held October 19-21, 2025 in San Diego. Electromed President and Chief Executive Officer Jim Cunniff will present on Monday, October 20 at 10:00 am PT. Interested parties may access a live webcast of the presentation using the following link Electromed LD Micro Main Event XIX Webcast. The link will also be posted on the Electromed Investor Relations website under Events & Presentations.
Institutional investors may register for the event and request one-on-one meetings through their LD Micro representative.
About Electromed, Inc.
Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.
Brad Nagel, Chief Financial Officer
(952) 758-9299
investorrelations@electromed.com
Mike Cavanaugh, Investor Relations
ICR Healthcare
(617) 877-9641
mike.cavanaugh@icrhealthcare.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/270251